CVS Health CorporationNYSE: CVS
Health Care · Health Care Services
$100.24
+7.41%
Vol: 666K
Research Digest
Monday, June 15, 2026
No significant overnight updates
No material news in the last 48 hours.
Previous Market Intelligence
13 daysJun 14No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 21CVS Health stock has surged about 24% in the past month as analysts raised price targets following Q1 earnings beat and raised 2026 guidance.Positive▶
CVS Health stock has risen about 24% over the past month on the strength of Q1 2026 results released May 6 and subsequent analyst upgrades. Q1 revenue of $100.43 billion beat the $94.99 billion estimate and EPS of $2.57 topped the $2.21 consensus, with all segments — Aetna, retail pharmacy and health services — beating expectations. CVS raised full-year 2026 adjusted EPS guidance to $7.30-$7.50 (from $7.00-$7.20) and now expects revenue of at least $405 billion (up from $400 billion). Multiple analysts raised targets: RBC Capital to $107 from $90, Evercore ISI to $105 from $100, and Truist to $102 from $98. On May 14, stockholders approved a new 2026 Incentive Compensation Plan. CVS also announced its Health100 technology subsidiary leveraging Google Cloud AI to deliver an integrated healthcare engagement platform. Shares trade around $95.71.
May 20CVS Health blows past Q1 estimates and raises 2026 guidance; analysts hike PTs across the boardPositive▶
CVS Health reported Q1 2026 revenue of $100.43B (vs $94.99B est) and EPS of $2.57 (vs $2.21 est), with all segments (Aetna insurer, retail pharmacy, health services) beating Wall Street. The company raised full-year EPS guidance to $7.30-$7.50 and revenue to at least $405B (up from $400B). The print extends CEO David Joyner's turnaround, which has cut $2B in costs and closed underperforming stores. CVS also unveiled Health100, a Google Cloud AI-powered health services subsidiary, and stockholders approved a new 2026 Incentive Compensation Plan on May 14. Analysts responded with PT hikes: RBC to $107 from $90, Evercore ISI to $105 from $100, BofA to $100 from $97.
May 19CVS Health stock hits 52-week high after Q1 2026 earnings beat and raised full-year guidancePositive▶
CVS Health reported Q1 2026 results on May 6 with revenue of $100.4 billion (up 6.2% YoY) and adjusted EPS of $2.57, both topping estimates. The company raised its full-year 2026 adjusted EPS outlook to $7.30-$7.50 and revenue guidance to at least $405 billion. Aetna's medical benefit ratio improved meaningfully to 84.6% from 87.3%, signaling progress in the insurance turnaround. Multiple analysts raised price targets in May, including RBC to $107, Evercore ISI to $105, and Truist to $102. CVS also launched Health100, an AI-powered healthcare engagement subsidiary in partnership with Google Cloud. Sentiment is strongly positive as the turnaround appears on track.
May 18No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 15CVS raises 2026 EPS guidance to $7.30-$7.50 after Q1 beat; faces new Rhode Island PBM lawsuit and prior $117.7M Medicare Advantage fraud settlementPositive▶
CVS Health reported Q1 2026 revenue up 6.2% YoY to $100.4B with adjusted EPS of $2.57 (vs. $2.25 prior year) and raised full-year adjusted EPS guidance to $7.30-$7.50 plus operating cash flow to at least $9.5B. Drivers included improved Health Care Benefits operating income, better Aetna medical cost management, and increased Rx volume from Rite Aid asset acquisitions. Morgan Stanley raised its price target to $106 from $93 (Overweight) and TD Cowen lifted to $110 from $105 (Buy). However, on May 7 the Rhode Island Attorney General filed suit against CVS Caremark and other PBMs alleging unfair and deceptive practices that increase drug costs. CVS also recently agreed to a $117.7M Medicare Advantage fraud settlement. Stock closed up 3.10% on May 13 in continued post-earnings strength. Risk: ongoing PBM regulatory and legal exposure could weigh on the Caremark segment.
May 14CVS Health shares surge 3.31% on May 12 hitting new 52-week high of $92.77; JPMorgan raises PT to $111 from $101 with Overweight rating amid 6-day winning streak (+22%).Positive▶
CVS Health shares surged 3.31% on May 12, 2026, hitting a new 52-week high of $92.77, extending a 6-day winning streak that delivered cumulative 22% gains. The rally followed JPMorgan raising its price target to $111 from $101 with an Overweight rating. Q1 2026 results released May 6 showed all segments — Aetna insurance, retail pharmacy, and health services — beating estimates; revenue rose 6.2% YoY to $100.4B, GAAP diluted EPS was $2.30, Adjusted EPS $2.57, and net income climbed 66% YoY to ~$3B. Full-year 2026 guidance was raised to $7.30-$7.50 adjusted EPS and revenue of at least $405B (up from $400B). CVS also launched Health100, an AI engagement platform with Google Cloud. Risks include the May 7 Rhode Island Attorney General lawsuit against CVS Caremark and other PBMs alleging unfair and deceptive practices that increase prescription drug costs, plus ongoing GLP-1/obesity drug cost pressures cited by the CEO on May 12.
May 13CVS Health hit a new 52-week high of $92.77 after Q1 2026 revenue of $100.4B (+6%) and net income of $3B (+66%); raised 2026 EPS guidance to $7.30-$7.50.Positive▶
CVS Health stock surged more than 7% on May 6, 2026 after Q1 2026 results beat estimates across every segment. Revenue rose 6% to $100.4B and net income came in at just under $3B, up 66% YoY. The medical benefit ratio improved to 84.6% from 87.3%. Aetna, retail pharmacy, and health services all surpassed expectations. The company raised 2026 guidance to $7.30-$7.50 EPS and revenue of at least $405B (up from $400B). The stock hit a 52-week high of $92.77 on May 11, with YTD returns of 16%. EVP Tilak Mandadi sold 69,551 shares on May 8 at an average of $89.58 for $6.23M total.
May 12CVS Health shares jumped 7.7% after Q1 2026 beat ($100.4B revenue, $2.57 adjusted EPS vs $2.21 consensus) and a guidance raise, but Rhode Island AG sued Caremark on May 7 over alleged PBM practices.Positive▶
CVS reported Q1 2026 revenue of $100.4 billion (up 6.2% YoY) and adjusted EPS of $2.57 versus $2.21 consensus, prompting a guidance raise: adjusted EPS to $7.30-$7.50 (from $7.00-$7.20) and revenue to at least $405 billion. The standout was Aetna's medical benefit ratio dropping to 84.6% from 87.3% a year earlier. Shares jumped roughly 7.7% post-print and traded to a new 52-week high near $86.89. The company also unveiled Health100, a Google Cloud-powered health technology subsidiary. Offsetting risk: on May 7 the Rhode Island Attorney General filed a lawsuit against CVS Caremark and other PBMs alleging unfair and deceptive practices that raise drug costs.
May 11CVS Health Q1 2026 earnings crushed estimates and raised full-year EPS guidance to $7.30-$7.50, sending shares up ~8% to a new 52-week high.Positive▶
On May 6, 2026, CVS Health reported adjusted EPS of $2.57 vs. $2.21 consensus (+16.3% beat) and revenue of $100.4B (+5.7% beat), with shares jumping 8.28% pre-market to $85.35 and later setting a new 52-week high near $86.89. The company raised full-year 2026 guidance: adjusted EPS to $7.30-$7.50 (from $7.00-$7.20), revenue to at least $405B (from $400B), and operating cash flow to at least $9.5B. Aetna's medical benefit ratio improved sharply to 84.6% from 87.3% YoY, the key driver of the beat. CVS also unveiled Health100, a new Google Cloud AI-powered healthcare engagement subsidiary. All segments (Aetna, retail pharmacy, health services) beat expectations. Risk: Aetna MBR improvement must be sustainable to justify the re-rating.
May 8CVS Health Q1 beats earnings and revenue, raises FY26 guidance; Aetna MBR improves to 84.6% from 87.3% YoY.Positive▶
CVS Health reported strong Q1 2026 results on May 6: adjusted EPS of $2.57 beat $2.21 consensus, revenue hit $100.4B vs $95.0B estimate (6.2% YoY growth). Company raised full-year 2026 guidance: adjusted EPS now $7.30-$7.50 (from $7.00-$7.20), GAAP EPS $6.24-$6.44 (from $5.94-$6.14). Stock surged 7.7% on strength across all segments—pharmacy, Aetna insurance, and health services. Key driver: Aetna medical benefit ratio improved dramatically to 84.6% from 87.3% YoY, showing improved cost controls. Revenue guidance also raised to $405B+ (from $400B+). Stock hit new 52-week high at $86.89; up 8.4% YTD.
May 6Q1 2026 earnings beat May 6; raised full-year 2026 guidance; Health100 AI subsidiary announcedPositive▶
CVS Health delivered strong Q1 2026 results with adjusted EPS of $2.57 (beating $2.20 estimate) and revenue of $100.43B (+6.2% YoY), beating consensus. Company raised full-year 2026 guidance to EPS of $6.24-$6.44 (prior $5.94-$6.14) and adjusted EPS of $7.30-$7.50 (prior $7.00-$7.20). All business segments exceeded expectations, including insurance, retail pharmacy, and health services. CVS announced Health100, a health tech subsidiary powered by Google Cloud AI for personalized healthcare engagement. Stock surged 6-7% on May 6, trading near 52-week highs. Aetna insurance business showed significant improvement.
May 5CVS Health CEO resigns; company cuts 2900 workers and expands biosimilar adoptionMixed▶
CVS Health CEO Karen Lynch stepped down, replaced by David Joyner. Company cutting 2,900 workers (~1% of workforce) for $2B cost reduction. Expanded biosimilar adoption with formulary updates effective July 1, 2026. Transitioning from Stelara to preferred low-cost biosimilar alternatives with $0 out-of-pocket for most members. Started selling mifepristone abortion pill post-FDA regulatory changes. Opening 20 pharmacy-only CVS Pharmacy locations. Closing hundreds of stores including Target pharmacies due to traffic, competition, workforce challenges. Stock at $81.96 with P/E 59.02 and 3.2% yield, up 12% last month. CVS heading into earnings with analyst target $96.58. Settlement $117.7M related to Medicare Advantage fraud. Cautious optimism on medium-term earnings.
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price above both MAs — bullish structure.